# G-HOPE-001: HCP commentary report

> 83 verified statements (4 from speakers with a confirmed clinical role) from 32 commentary sources · 9 findings · updated Oct 27, 2026

## Report

- Trial: A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT ID: NCT06238843
- Registry: https://clinicaltrials.gov/study/NCT06238843
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-27
- Last checked: 2026-10-27
- Release hash: ca3829e05e5a9ab9dfc9c8e7bccf07e239a0703508877592e0ead1d97829453a

## Counts

- HCP commentary sources screened: 51
- Sources cited by verified statements: 32
- Verified statements: 83
- From speakers with a confirmed clinical role: 4
- Findings: 9
- People found in screened sources: 16
- People identity-verified: 11
- Voices cited: 16
- Organisational or shared accounts (not counted as people): 8

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on G-HOPE-001 in the sources reviewed for this edition leads to one open question: What evidence, patient-selection information and testing conditions are needed to translate the favorable signal into an appropriate later-line option, especially after zolbetuximab and outside the studied Asian population? Its leading findings: (1) post-zolbetuximab activity and geographic applicability limit the adoption conclusions drawn. (2) favorable efficacy reactions refer to different interim accounts, not one interchangeable result set. (3) A possible gastrointestinal tolerability advantage is welcomed, but remains conditional. 6 more findings follow. 32 of 51 screened sources are cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What evidence, patient-selection information and testing conditions are needed to translate the favorable signal into an appropriate later-line option, especially after zolbetuximab and outside the studied Asian population?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Post-zolbetuximab activity and geographic applicability limit the adoption conclusions drawn
- F2. Favorable efficacy reactions refer to different interim accounts, not one interchangeable result set
- F3. A possible gastrointestinal tolerability advantage is welcomed, but remains conditional
- F4. Expression thresholds and ADC design make cross-program rankings unsafe
- F5. Borderline and discordant results prompt investigation, not averaging or rounding into eligibility
- F6. Retesting is advocated, but its urgency depends on prior treatment and feasibility
- F7. Testing capacity, report detail and oncology–pathology dialogue are practical readiness requirements
- F8. Development enthusiasm extends to combinations, without establishing combination benefit
- F9. Regulatory progress is discussed as prospective access, not current availability everywhere

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 6 | 4 | 3 | 3 | none recorded | 2 |
| F2 | 21 | 19 | 19 | 15 | none recorded | 3 |
| F3 | 17 | 15 | 12 | 11 | recorded | 4 |
| F4 | 11 | 9 | 6 | 6 | none recorded | 3 |
| F5 | 8 | 7 | 1 | 2 | none recorded | 3 |
| F6 | 3 | 2 | 1 | 1 | none recorded | 3 |
| F7 | 11 | 10 | 1 | 2 | none recorded | 2 |
| F8 | 11 | 9 | 8 | 8 | none recorded | 2 |
| F9 | 8 | 8 | 8 | 5 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 1 | 3 | 0 | 1 | 1 | 7 | 2 | 3 posts and articles | yes |
| F2 | 6 | 1 | 0 | 1 | 13 | 22 | 3 | 16 posts and articles, 3 podcasts and video | yes |
| F3 | 8 | 1 | 0 | 3 | 5 | 19 | 2 | 11 posts and articles, 1 podcast or video | yes |
| F4 | 5 | 1 | 0 | 3 | 2 | 12 | 2 | 5 posts and articles, 1 podcast or video | yes |
| F5 | 4 | 1 | 1 | 0 | 2 | 9 | 0 | 1 podcast or video | yes |
| F6 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 1 podcast or video | yes |
| F7 | 7 | 3 | 0 | 0 | 1 | 13 | 0 | 1 podcast or video | yes |
| F8 | 5 | 2 | 1 | 0 | 3 | 11 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F9 | 1 | 0 | 0 | 0 | 7 | 8 | 0 | 6 posts and articles, 2 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: progression free survival(PFS): F1 (1 shared claims), F2 (17 shared claims), F3 (9 shared claims), F8 (2 shared claims)
- Primary endpoint: overall survival(OS): F1 (3 shared claims), F2 (14 shared claims), F3 (6 shared claims), F8 (2 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (9 shared claims), F3 (6 shared claims)
- Population and setting: F1 (3 shared claims), F2 (11 shared claims), F3 (5 shared claims), F8 (1 shared claims)
- The comparison: F1 (1 shared claims), F2 (13 shared claims), F3 (8 shared claims), F8 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (8 shared claims), F3 (17 shared claims), F4 (3 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (6 shared claims), F3 (4 shared claims), F8 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 83 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 32 | Counts free |
| Speaker attribution for cited voices | 16 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: progression free survival(PFS) | discussed | 21 | 20 |
| Primary endpoint: overall survival(OS) | discussed | 20 | 17 |
| Secondary endpoints | discussed | 11 | 11 |
| Population and setting | discussed | 13 | 12 |
| The comparison | discussed | 13 | 13 |
| Safety and tolerability | discussed | 18 | 13 |
| Design and conduct | discussed | 7 | 8 |
| Specimen heterogeneity, discordance and borderline eligibility | discussed | 9 | 1 |
| Prior zolbetuximab and conditional rebiopsy before an ADC | discussed | 7 | 4 |
| Assay alignment, reporting and testing-service readiness | discussed | 11 | 1 |
| Cross-program interpretation, payloads and Fc-design hypotheses | discussed | 11 | 6 |
| Geographic applicability and the threshold for a global-standard judgment | discussed | 7 | 6 |
| Development interest, earlier evidence and future combinations | discussed | 12 | 9 |
| Regulatory milestones and prospective access | discussed | 7 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 44 | 28 |
| Bluesky threads | 4 | 1 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |

- Screened window: 2024-05-07 to 2026-10-26
- Cited window: 2024-05-07 to 2026-10-26
- Retrieved: 2026-10-27

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Registry: NCT06238843 (https://clinicaltrials.gov/study/NCT06238843)
- Study IDs: CIBI343A301
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 464 (actual)
- Start: 2024-06-30 (actual)
- Primary completion: 2026-12-30 (estimated)
- Primary endpoint: progression free survival(PFS) (within approximately 20 months)
- Primary endpoint: overall survival(OS) (within approximately 26 months)
- Intervention: Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） (drug)
- Intervention: IBI343 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on later-line efficacy of a claudin-targeted antibody–drug conjugate versus standard treatment in advanced gastroesophageal adenocarcinoma.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 61 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Some potentially relevant discussion could not be read or fully assessed, and unnamed or differently transcribed references may be missing.
- No full protocol or exact-trial results publication was available. Registry material describes planned methods and does not independently validate numerical findings shared in commentary.
- Enrolment figures, interim-analysis labels and some outcomes differ across posts. These differences are preserved rather than reconciled without supporting information.
- Prior zolbetuximab exposure was described as unreported in a release. This does not establish that exposure was absent or determine efficacy after that treatment.
- The material includes individual opinions, organization and news accounts, and relayed findings. Source totals and reposts must not be interpreted as independent clinician counts or consensus.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Gastrointestinal safety differentiation, Fc-design explanations and expression requirements include expectations and hypotheses, not demonstrated head-to-head advantages. Different severe-adverse-event definitions are not interchangeable.
- Regulatory statements are time-specific reports. Independently confirmed current product-label and local-access information was unavailable.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-27: current edition, corrected 2026-10-27
  - Correction 2026-10-27: A summary sentence now uses the wording of the finding it summarizes.

Last checked for new commentary 2026-10-27. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (83 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (11 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/g-hope-001-nct06238843
- Agents: POST https://www.erudio.com/api/orders with {"report": "g-hope-001-nct06238843", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=g-hope-001-06238843

## Cite

Erudio Health. G-HOPE-001 (NCT06238843): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 27, 2026. https://www.erudio.com/reports/g-hope-001-nct06238843

## Machine access

- JSON: https://www.erudio.com/reports/g-hope-001-nct06238843.json
- Markdown: https://www.erudio.com/reports/g-hope-001-nct06238843.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "g-hope-001-06238843"}`